Manufacturer

Country

Document

0.33 MB

Registration Date	3 Sep 2022
Revision Date	3 Sep 2022
Share

Onpattro

(0)

Medicine Pharmaceuticals

Polyneuropathy Drug

Drug Information

Generic

Patisiran

Drug Class

si RNA

Therapeutic Class

RNA Interference (RNAi) Therapy

Dosage form

Solution

Route of Administration

Intravenous Injection

Therapeutic Area

1.Polyneuropathy

Nanomaterials

Manufacturer Asserted

Lipid Nanoparticle

Biological Nanoparticles

Indication

ONPATTRO is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). ONPATTRO is used in adults only.

Benefit

Onpattro contains patisaran, a double-stranded small interfering ribonucleic acid (siRNA) formulated in the form of a lipid complex. Patisiran is used to treat polyneuropathy (damage of multiple nerves throughout the body) in adults with hereditary transthyretin-mediated amyloidosis (hATTR).